Skip to main content

Stockpickr: The Top Dividend 'Aristocrats'

These stocks offer high yield, consistent growth and safety.

Jim Cramer recently featured the S&P Dividend Aristocrats on his "Mad Money" TV show. This Stockpickr portfolio consists of S&P 500 companies that have increased their dividends every year for the past 25 years.

These names offer investors big rewards, because what starts off, perhaps, as a 1% yield when you first buy the stock could end up becoming a yield of 20% or more when compared with your initial purchase costs.

The fact that these companies have increased their dividends every year for the past 25 years gives you a significant margin of safety.

Of course there are no guarantees, but chances are these are well-managed companies with increasing cash flows and reason to believe they'll increase those dividends in the future.

There are three portfolios worth looking at:

Let's take a look at the stocks that appear to have the most margin of safety in terms of their balance sheets, their historical growth, their yield, etc.

First up, there's

Automatic Data Processing

(ADP) - Get Free Report

. This company is a rock. (Of course, in the interest of full disclosure, I should mention that I temped at ADP for a week in 1987, making about $8 an hour. I accidentally put the wrong checks in the wrong envelopes, and after a week they had had enough of me.)

ADP processes payroll and benefits packages for thousands of companies. If you hire ADP to handle your payroll, chances are you're never going to take on that task in-house again.

ADP has $1.5 billion in the bank and no debt. It has $2.2 billion in EBITDA and trades at only 10 times EBITDA. My only concern here -- especially if I were an ADP employee -- is that the company can easily get taken over by raiders who leverage up, buy the company and live off the massive cash flows.

Is the company still growing? Last year it generated earnings of $1.49 a share. This year, analysts expect EPS of $1.83, and $2.16 next year. It also has a 2% yield.

Another company that has increased dividends for the past 25 years and is cheap relative to its historical valuation right now is



. The company makes and distributes chemicals and kits for genomic research, biotech research and pharmaceutical development.

Sigma-Aldrich offers an excellent, indirect way to play the aging baby boomer trend. Because of the size of that generation, you can expect more research, more drugs and more development in the biotech/pharma space over the next 50 years.

Sigma-Aldrich has a rock-solid balance sheet with $173 million in cash, about $500 million of debt, but with $509 million in EBITDA and growing. Again, at 11 times cash flows, the only thing that worries me is that the company can get acquired too quickly to enjoy the next 25 years of dividend increases.

Sigma-Aldrich is also listed in the

Claymore/Sabrient Insider ETF

, an exchange-traded fund that tracks companies where there's been heavy insider buying and analysts recently have increased estimates.

In fact, about 90 days ago, analysts had expected, on average, Sigma-Aldrich to hit $2.15 in EPS for 2007. Now they expect $2.20. And recently, several officers of the company have bought Sigma-Aldrich shares on the open market. Other stocks on the Claymore/Sabrient Insider ETF include

MGM Mirage

(MGM) - Get Free Report





One of Jim Cramer's favorites on the Aristocrats list is drugstore chain



. For the past 20 years,


has haunted Walgreen investors. There's always the fear that Wal-Mart can infringe on Walgreen's business.

That said, however, Walgreen has a lot of cushion, with about $1 billion cash in the bank, no debt and EBITDA of $3.8 billion on an enterprise value of $45 billion, giving it an enterprise value over EBITDA of just 12.

Walgreen's 22-year chart offers a not-so-bad picture either:

Walgreen (WAG)

Here are some of my other favorite dividend portfolios:

At the time of publication, Altucher and/or his fund had no positions in stocks mentioned, although positions may change at any time.

James Altucher is a managing partner at Formula Capital, an alternative asset management firm that runs several quantitative-based hedge funds as well as a fund of hedge funds. He is also the author of

Trade Like a Hedge Fund


Trade Like Warren Buffett

. Under no circumstances does the information in this column represent a recommendation to buy or sell stocks. Altucher appreciates your feedback;

click here

to send him an email. has a revenue-sharing relationship with Trader's Library under which it receives a portion of the revenue from purchases by customers directed there from